Appendix 4C and Quarterly Activities Report - June 2026
Filed with ASX · · 8 pages · English
Summary by 6ix AI
The report highlights key developments, including the strengthening of clinical leadership and the expansion of its clinical trial programs. Invion reported a cash position at the end of the quarter and outlined significant cash outflows related to research and development and administrative costs. The company anticipates receiving additional funding from research and development tax incentives in the near future.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Invion
- Photosoft Platform Expands to Eye Diseases Via Partnership
- Appendix 4C and Quarterly Activities Report - March 2026
- Skin Cancer Trial Moves to BCC With More Encouraging Signals
- Appendix 4D and Half Year Financial Report
- Appendix 4C and Quarterly Activities Report - December 2025
Later from Invion
- Recruitment Conclusion for Ph 1 NMSC Trial & Advance to Ph 2
- Funding Agreements Cover Up to 85% of Clinical Trials Costs
- Appendix 4C and Quarterly Activities Report - September 2026
Follow Invion into a list and get an email when it puts out news.
Follow Invion